NORTHSTAR ASSET MANAGEMENT Co Has $6.40 Million Position in Danaher Corporation $DHR

NORTHSTAR ASSET MANAGEMENT Co decreased its holdings in shares of Danaher Corporation (NYSE:DHR) by 2.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,385 shares of the conglomerate’s stock after selling 800 shares during the quarter. Danaher comprises approximately 1.5% of NORTHSTAR ASSET MANAGEMENT Co’s holdings, making the stock its 15th largest position. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Danaher were worth $6,397,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in DHR. Nuveen LLC bought a new position in Danaher during the first quarter worth $833,941,000. Invesco Ltd. grew its position in Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Baird Financial Group Inc. raised its position in shares of Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after buying an additional 1,072,617 shares during the last quarter. Generation Investment Management LLP grew its position in Danaher by 33.2% during the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock worth $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC raised its holdings in Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after acquiring an additional 722,636 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Trading Up 0.1%

DHR stock opened at $223.03 on Friday. The business has a fifty day moving average price of $202.73 and a 200 day moving average price of $198.36. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.22. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The stock has a market capitalization of $157.54 billion, a price-to-earnings ratio of 45.99, a P/E/G ratio of 3.41 and a beta of 0.77.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period last year, the company posted $1.71 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s payout ratio is 26.39%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Guggenheim reissued a “buy” rating and set a $250.00 price objective on shares of Danaher in a report on Wednesday, July 23rd. Evercore ISI increased their price objective on shares of Danaher from $226.00 to $245.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Royal Bank Of Canada set a $241.00 target price on shares of Danaher in a research report on Tuesday, September 2nd. Barclays lifted their price objective on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, UBS Group dropped their target price on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.